660 related articles for article (PubMed ID: 24607790)
1. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
2. In vivo visualisation of nanoparticle entry into central nervous system tissue.
Henrich-Noack P; Prilloff S; Voigt N; Jin J; Hintz W; Tomas J; Sabel BA
Arch Toxicol; 2012 Jul; 86(7):1099-105. PubMed ID: 22422342
[TBL] [Abstract][Full Text] [Related]
3. Major effects on blood-retina barrier passage by minor alterations in design of polybutylcyanoacrylate nanoparticles.
You Q; Hopf T; Hintz W; Rannabauer S; Voigt N; van Wachem B; Henrich-Noack P; Sabel BA
J Drug Target; 2019 Mar; 27(3):338-346. PubMed ID: 30280953
[TBL] [Abstract][Full Text] [Related]
4. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
Rempe R; Cramer S; Hüwel S; Galla HJ
Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549
[TBL] [Abstract][Full Text] [Related]
5. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation.
Weiss CK; Kohnle MV; Landfester K; Hauk T; Fischer D; Schmitz-Wienke J; Mailänder V
ChemMedChem; 2008 Sep; 3(9):1395-403. PubMed ID: 18613205
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
7. How Nanoparticle Physicochemical Parameters Affect Drug Delivery to Cells in the Retina via Systemic Interactions.
You Q; Sokolov M; Grigartzik L; Hintz W; van Wachem BGM; Henrich-Noack P; Sabel BA
Mol Pharm; 2019 Dec; 16(12):5068-5075. PubMed ID: 31609624
[TBL] [Abstract][Full Text] [Related]
8. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
9. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle surface charges alter blood-brain barrier integrity and permeability.
Lockman PR; Koziara JM; Mumper RJ; Allen DD
J Drug Target; 2004; 12(9-10):635-41. PubMed ID: 15621689
[TBL] [Abstract][Full Text] [Related]
11. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo.
Kolter M; Ott M; Hauer C; Reimold I; Fricker G
J Control Release; 2015 Jan; 197():165-79. PubMed ID: 25445700
[TBL] [Abstract][Full Text] [Related]
12. Transport of drugs across the blood-brain barrier by nanoparticles.
Wohlfart S; Gelperina S; Kreuter J
J Control Release; 2012 Jul; 161(2):264-73. PubMed ID: 21872624
[TBL] [Abstract][Full Text] [Related]
13. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.
Costantino L; Gandolfi F; Tosi G; Rivasi F; Vandelli MA; Forni F
J Control Release; 2005 Nov; 108(1):84-96. PubMed ID: 16154222
[TBL] [Abstract][Full Text] [Related]
14. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle.
Lu W; Wan J; She Z; Jiang X
J Control Release; 2007 Mar; 118(1):38-53. PubMed ID: 17240471
[TBL] [Abstract][Full Text] [Related]
15. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
16. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.
Zhang B; Sun X; Mei H; Wang Y; Liao Z; Chen J; Zhang Q; Hu Y; Pang Z; Jiang X
Biomaterials; 2013 Dec; 34(36):9171-82. PubMed ID: 24008043
[TBL] [Abstract][Full Text] [Related]
17. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Kuo YC; Su FL
Int J Pharm; 2007 Aug; 340(1-2):143-52. PubMed ID: 17418986
[TBL] [Abstract][Full Text] [Related]
18. Quaternary ammonium beta-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier.
Gil ES; Li J; Xiao H; Lowe TL
Biomacromolecules; 2009 Mar; 10(3):505-16. PubMed ID: 19216528
[TBL] [Abstract][Full Text] [Related]
19. β-cyclodextrin-poly(β-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier.
Gil ES; Wu L; Xu L; Lowe TL
Biomacromolecules; 2012 Nov; 13(11):3533-41. PubMed ID: 23066958
[TBL] [Abstract][Full Text] [Related]
20. Surface engineering of inorganic nanoparticles for imaging and therapy.
Nam J; Won N; Bang J; Jin H; Park J; Jung S; Jung S; Park Y; Kim S
Adv Drug Deliv Rev; 2013 May; 65(5):622-48. PubMed ID: 22975010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
